Elepsia Xr is a drug owned by Tripoint Therapeutics. It is protected by 5 US drug patents filed in 2015 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 31, 2027. Details of Elepsia Xr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8425938 | Pharmaceutical composition |
Feb, 2026
(1 year, 6 months from now) | Active |
| US8535717 | Pharmaceutical composition |
Feb, 2026
(1 year, 6 months from now) | Active |
| US8163306 | Oral drug delivery system |
Sep, 2027
(3 years from now) | Active |
| US8470367 | Oral drug delivery system |
Oct, 2027
(3 years from now) | Active |
| US8431156 | Pharmaceutical composition |
Oct, 2027
(3 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Elepsia Xr's patents.
Latest Legal Activities on Elepsia Xr's Patents
Given below is the list of recent legal activities going on the following patents of Elepsia Xr.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 Oct, 2023 | US8163306 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Mar, 2021 | US8535717 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Dec, 2020 | US8470367 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Oct, 2020 | US8431156 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Oct, 2020 | US8425938 |
| Post Issue Communication - Certificate of Correction | 25 Feb, 2020 | US8470367 |
| Email Notification | 19 Oct, 2019 | US8470367 |
| Filing Receipt - Corrected | 18 Oct, 2019 | US8470367 |
| Mail-Petition Decision - Granted | 18 Oct, 2019 | US8470367 |
| Email Notification | 18 Oct, 2019 | US8470367 |
US patents provide insights into the exclusivity only within the United States, but Elepsia Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Elepsia Xr's family patents as well as insights into ongoing legal events on those patents.
Elepsia Xr's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Elepsia Xr's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 31, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Elepsia Xr Generics:
Levetiracetam is the generic name for the brand Elepsia Xr. 76 different companies have already filed for the generic of Elepsia Xr, with Prinston Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Elepsia Xr's generic
About Elepsia Xr
Elepsia Xr is a drug owned by Tripoint Therapeutics. It is used for addressing a variety of psychiatric conditions and managing depression and anxiety symptoms. Elepsia Xr uses Levetiracetam as an active ingredient. Elepsia Xr was launched by Tripoint in 2018.
Market Authorisation Date:
Elepsia Xr was approved by FDA for market use on 20 December, 2018.
Active Ingredient:
Elepsia Xr uses Levetiracetam as the active ingredient. Check out other Drugs and Companies using Levetiracetam ingredient
Treatment:
Elepsia Xr is used for addressing a variety of psychiatric conditions and managing depression and anxiety symptoms.
Dosage:
Elepsia Xr is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1GM | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 1.5GM | TABLET, EXTENDED RELEASE | Discontinued | ORAL |